Advertisement

Current Treatment Options in Neurology

, Volume 6, Issue 3, pp 191–200 | Cite as

Pain in Parkinson’s disease

  • Jacob I. Sage
Article

Opinion statement

Pain is reported by nearly 50% of patients with Parkinson’s disease. In some patients, it can be more debilitating than the motor deficits. In order to identify the appropriate treatment strategy for each patient, it is useful to categorize pain syndromes as follows: 1) low DOPA (end of dose wearing off, diphasic, or early morning) painful states are associated with inadequate levels of dopamine receptor stimulation; 2) high DOPA (peak dose) painful states occur at times of maximum levodopa efficacy; and 3) many patients report pain that has no obvious relation to dopaminergic medications or may even be caused by other conditions. Low DOPA painful states are best treated by trying to provide more continuous dopaminergic stimulation and thereby reduce or prevent the number and duration of “off” periods. Adding or increasing the dose of direct-acting dopamine receptor agonists or of catechol-o-methyl transferase inhibitors is the best first-line strategy. Other approaches include increasing the frequency of immediate-release levodopa preparations or using controlled-release preparations. More invasive approaches should be considered only when simpler methods fail. These include deep brain stimulation to the pallidum or the subthalamic nucleus, or direct duodenal continuous infusion of levodopa in patients who are unable to undergo surgery. Pain associated with excessive dopaminergic stimulation usually is a result of dystonia or severe chorea. Reduction of levodopa is the first step in attempting to diminish high DOPA states, followed by reduction or cessation of other dopaminergic agents such as selegiline, catechol-o-methyl transferase inhibitors, or direct-acting dopamine receptor agonists. Adding amantadine can reduce chorea significantly and it should be tried if the potential and actual side effects are tolerable to the patient. Deep brain stimulation is a good final option if medication adjustments are ineffective. Nonspecific pains of Parkinson’s disease can be difficult to treat. The effective use of central pain suppressant or analgesics is anecdotal and difficult to verify. In untreated early disease, generalized pain or pain related to joint or muscle immobility may be reduced by effective treatment of the underlying Parkinson’s disease.

Keywords

Levodopa Dystonia Deep Brain Stimulation Main Side Effect Selegiline 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Charcot JM: Oeuvres Completes, vol 1. Paris: Bureaux du Progres Medical; 1892.Google Scholar
  2. 2.
    Goetz CG, Tanner CM, Levy M, et al.: Pain in Parkinson’s disease. Mov Disord 1986, 1:45–49.PubMedCrossRefGoogle Scholar
  3. 3.
    Ford B.Pain in Parkinson’s disease. Clin Neurosci 1998, 5:63–72. A good recent article.PubMedCrossRefGoogle Scholar
  4. 4.
    Hillen ME, Sage JI: Nonmotor fluctuations in patients with Parkinson’s disease. Neurology 1996, 47:1180–1183.PubMedGoogle Scholar
  5. 5.
    McHale DM, Sage JI, Sonsalla PK, Vitagliano D: Complex dystonia of Parkinson’s disease: clinical features and relation to plasma levodopa profile. Clin Neuropharmacol 1990, 13:164–170.PubMedCrossRefGoogle Scholar
  6. 6.
    Quinn NP, Lang AE, Koller WC, Marsden CD: Painful Parkinson’s disease. Lancet 1986, 1:1366–1369.PubMedCrossRefGoogle Scholar
  7. 7.
    Waseem S, Gwinn-Hardy K: Pain in Parkinson’s disease. Postgrad Med 2001, 110:33–40.PubMedGoogle Scholar
  8. 8.
    Sage JI, Kortis HI, Sommer W: Evidence for the role of spinal cord systems in Parkinson’s disease-associated pain. Clin Neuropharmacol 1990, 13:171–174.PubMedCrossRefGoogle Scholar
  9. 9.
    Comella CA, Goetz CG: Akathisia in Parkinson’s disease. Mov Disord 1994, 9:545–549.PubMedCrossRefGoogle Scholar
  10. 10.
    Lang AE, Johnson K: Akathisia in idiopathic Parkinson’s disease. Neurology 1987, 37:477–481.PubMedGoogle Scholar
  11. 11.
    Ford B, Louis ED, Greene P, Fahn S: Oral and genital pain syndromes in Parkinson’s disease. Mov Disord 1996, 11:421–426.PubMedCrossRefGoogle Scholar
  12. 12.
    Snider SR, Fahn S, Isgreen WP, Cote LJ: Primary sensory symptoms in parkinsonism. Neurology 1976, 26:423–429.PubMedGoogle Scholar
  13. 13.
    Schott GD: Pain in Parkinson’s disease. Pain 1985, 22:407–411.PubMedCrossRefGoogle Scholar
  14. 14.
    Cleeves L, Findley L: Frozen shoulder and other shoulder disturbances in Parkinson’s disease. J Neurol Neurosurg Psychiatry 1989, 52:813–814.PubMedCrossRefGoogle Scholar
  15. 15.
    Linazasoro G, Marti Masso JF, Suarez A: Nocturnal akathisia in Parkinson’s disease: treatment with clozapine. Mov Disord 1993, 8:171–174.PubMedCrossRefGoogle Scholar
  16. 16.
    Juncos JL: Clozapine: treatment of parkinsonian pain syndromes. Mov Disord 1996, 11:603–604.Google Scholar
  17. 17.
    Quinn NP, Marsden CD: Lithium for painful dystonia in Parkinson’s disease. Lancet 1986, 1:1366–1369.PubMedCrossRefGoogle Scholar
  18. 18.
    Lees AJ, Shaw KM, Stern GM: Baclofen in Parkinson’s disease. J Neurol Neurosurg Psychiatry 1984, 41:707–708.Google Scholar
  19. 19.
    Chana P, Marinis A, Barrientos N.Gabapentin and motor fluctuations in Parkinson’s disease. Mov Disord 1997, 12:608.PubMedCrossRefGoogle Scholar
  20. 20.
    Syed N, Murphy J, Zimmerman T, et al.: Ten years’ experience with enteral levodopa infusions for motor fluctuations in Parkinson’s disease. Mov Disord 1998, 13:336–338.PubMedCrossRefGoogle Scholar
  21. 21.
    Loher TJ, Burgunder JM, Weber S, et al.: Effect of chronic pallidal deep brain stimulation on off period dystonia and sensory symptoms in advanced Parkinson’s disease. J Neurol Neurosurg Psychiatry 2002, 73:395–399.PubMedCrossRefGoogle Scholar
  22. 22.
    Mark MH, Sage JI: Levodopa-associated hemifacial dystonia. Mov Disord 1991, 6:383.PubMedCrossRefGoogle Scholar
  23. 23.
    Snider SR, Fahn S, Cote LJ, Isgreen WP: Pain, paresthesia and parkinsonism. N Engl J Med 1975, 293:200.PubMedGoogle Scholar
  24. 24.
    Starkstein SE, Preziosi TJ, Robinson RG: Sleep disorders, pain, and depression in Parkinson’s disease. Eur Neurol 1991, 31:352–355.PubMedGoogle Scholar
  25. 25.
    Goetz CG, Wilson RS, Tanner CM, Garron DC: Relationships among pain, depression and sleep alterations in Parkinson’s disease. In Advances in Neurology. Edited by Yahr MD, Bergmann KJ. Raven Press, New York; 1986:345–347.Google Scholar
  26. 26.
    Pacchetti C, Albani G, Martignoni E, et al.: “Off” painful dystonia in Parkinson’s disease treated with botulinum toxin. Mov Disord 1995, 10:333–336.PubMedCrossRefGoogle Scholar
  27. 27.
    Factor SA, Molho ES: Emergency department presentations of patients with Parkinson’s disease. Am J Emerg Med 2000, 18:209–215.PubMedCrossRefGoogle Scholar

Copyright information

© Current Science Inc 2004

Authors and Affiliations

  • Jacob I. Sage
    • 1
  1. 1.Department of NeurologyRobert Wood Johnson Medical School, University of Medicine and Dentistry of New JerseyNew BrunswickUSA

Personalised recommendations